Why these huge costs?   A lot of the problem is the sheer complexity of making a new drug, plus, of course, the   burdens of taxes and regulation —  more on that later.    Yet in the meantime, American pharma companies know that their main chance to recoup their investment is in the US market, and so that’s what they seek to do —   